Avista Pharma Solutions, Inc.
Durham, NC Doing business as Cambrex Avista Pharma Solutions, Inc.
- UEI
- GRKKCA8LJNE4
- CAGE
- 1YBV9
- Primary NAICS
- 325411 Medicinal and Botanical Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3501 Tricenter Blvd c, Durham, NC 27713, USA
- Website
- cambrex.com
- Founded
- 1981
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Acquisition of cgmp-grade GS-441524 for the treatment of covid-19 | National Institute on Drug Abuse | $581,604 | |
| Acquisition of cgmp-grade GS-441524 for the treatment of covid-19 | National Institute on Drug Abuse | $2,086,294 | |
| GLP efficacy testing for EPA registration of a novel disinfecting/sanitizing wipe for mulation, quote #USD03.040115 | Southeast Area | $20,200 | |
| Adopt a trout radio tags | Wyoming Region | $0 | |
| Pre-saturated towlette efficacy testing, 28 samples | Central Program Planning Coordination and Support | $22,680 |
About Avista Pharma Solutions, Inc.
Avista Pharma Solutions, Inc., doing business as Cambrex, is a corporate entity registered in SAM.gov since 2002, with a foreign-owned, for-profit organizational structure based in Durham, North Carolina. The company specializes in pharmaceutical manufacturing and development, with a particular focus on producing high-quality drug substances for clinical research and medical applications. As a pharmaceutical solutions provider, Avista Pharma Solutions, Inc. is equipped to manufacture complex drug substances with specialized production capabilities, including current Good Manufacturing Practice (cGMP) grade materials.
The company has primarily engaged in federal contract work with the National Institutes of Health (NIH), specifically the National Center for Advancing Translational Sciences, focusing on critical COVID-19 research initiatives. Two significant prime federal contract awards totaling approximately $2.7 million have been secured for the production of cGMP-grade GS-441524, a potential COVID-19 treatment drug substance. These purchase orders involved manufacturing 2-3 kilograms of specialized pharmaceutical materials to support preclinical and Phase I clinical studies, with performance occurring at their Durham, North Carolina facility. The contracts, awarded in December 2020 and February 2022, were competitively procured without specific set-aside designations and were aimed at evaluating the drug's safety, tolerability, efficacy, and optimal dosage for human use. Additionally, Avista Pharma Solutions, Inc. has been involved in a sub-contract award with Research Triangle Institute, further demonstrating their capacity to support complex pharmaceutical research and development projects for federal agencies.
Quick answers
What is Avista Pharma Solutions, Inc.'s UEI?
Avista Pharma Solutions, Inc.'s Unique Entity ID (UEI) in SAM.gov is GRKKCA8LJNE4.
What is Avista Pharma Solutions, Inc.'s CAGE code?
Avista Pharma Solutions, Inc.'s CAGE code is 1YBV9.
What is Avista Pharma Solutions, Inc.'s primary NAICS code?
Avista Pharma Solutions, Inc.'s primary NAICS code is 325411 (Medicinal and Botanical Manufacturing).
Where is Avista Pharma Solutions, Inc. located?
Avista Pharma Solutions, Inc.'s physical address in SAM.gov is 3501 Tricenter Blvd c, Durham, NC 27713, USA.
Is Avista Pharma Solutions, Inc. registered in SAM.gov?
Yes. Avista Pharma Solutions, Inc.'s SAM.gov registration is active through December 10, 2026.
What is Avista Pharma Solutions, Inc.'s most recent federal award?
Avista Pharma Solutions, Inc.'s most recent federal contract award is Acquisition of cgmp-grade GS-441524 for the treatment of covid-19 (75N95022P00137), from National Institute on Drug Abuse, on February 18, 2022.
On GovTribe
See Avista Pharma Solutions, Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors